Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, Hellwig K, Hutton GJ, McCombe P, Moore M, Rog D, Schneider JR, Simm RF, Sousa L, Vincent SG, Chung L, Daizadeh N, Mitchell C, Compston DAS; CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.
Oh J, et al.
Mult Scler Relat Disord. 2020 Aug;43:102146. doi: 10.1016/j.msard.2020.102146. Epub 2020 May 6.
Mult Scler Relat Disord. 2020.
PMID: 32498033
Free article.
Clinical Trial.